Cytopia is developing CYT997, a new anti-cancer agent that disrupts tumour blood vessels. CYT997 is currently being investigated in a Phase I / II clinical trial in a variety of cancers.
Read more
Myeloproliferative disorders (MPDs) are debilitating, and potentially fatal, diseases of blood cell production. Cytopia is developing JAK2 inhibitors for the treatment of myeloproliferative disease, cancer and pulmonary hypertension (PAH). The company's lead drug, CYT387, is expected to enter Ph I clinical trials late 2009.
Read more
Quick Links
Link Market Services Ltd provide the share registry services to all Cytopia shareholders CIBC Mellon Trust Company
CIBC Mellon Trust Company (Toronto, CA) provide the Investor services to all YM BioSciences shareholders
Cytopia has a strong and growing intellectual property platform Intellectual Property / Patents
Cytopia has a strong and growing intellectual property platform
Archive of Cytopia's annual reports Annual Reports
Archive of Cytopia's annual reports

The merger between Cytopia and YM BioSciences has now formally been implemented pursuant to the Scheme of Arrangement conducted by Cytopia. Cytopia is now a wholly-owned subsidiary of YM BioSciences Inc. All Cytopia shareholders registered at 25 January 2010 have been issued with new shares in YM BioSciences Inc. For detailed information on YM Shares please click here

The current Cytopia website will remain active, and will update shareholders on all activities within the two companies. Cytopia will continue to update all interested parties registered on the mailing list including Cytopia shareholders who have previously registered .

For more information on YM BioSciences please visit www.ymbiosciences.com .

To read the latest YM BioSciences News click here

.

30 March 2010 Announcement from YM BioSciences Inc.
Early expansion of ongoing CYT387 Phase I/II Clinical study

15 March 2010 Announcement from YM BioSciences Inc.
AACR acceptance of two Nimotuzumab poster presentations

10 March 2010 Announcement from YM BioSciences Inc.
YM BioSciences closes US$17.5 million financing
8 March 2010 Announcement from YM BioSciences Inc.
YM BioSciences increases offering size to approximately US$17.5 million
5 March 2010 Announcement from YM BioSciences Inc.
YM BioSciences ro raise approximately US$15 million
2 March 2010 Announcement from YM BioSciences Inc.
YM sees nimotuzumab license unaffected by civil claim against licensor
11 February 2010 Announcement from YM BioSciences Inc.
Presentations of CYT387 and CYT997 data at interantional cancer conference
10 February 2010 Announcement from YM BioSciences Inc.
YM BioSciences granted two US patents for AeroLEF(R)

To subscribe or unsubscribe to Cytopia email Announcements, please email cytopia@cytopia.com.au with the word 'subscribe' or 'unsubscribe' in the subject line
Copyright © 2009 by Cytopia Ltd. All rights reserved. | Site use and privacy policy